IPO - Enveric Biosciences, Inc.

Form Type: 424B4

Filing Date: 2025-02-03

Corporate Action: Ipo

Type: New

Accession Number: 000149315225004528

Filing Summary: Enveric Biosciences, Inc. is filing for an initial public offering (IPO) of its series CRedeemable Preferred Stock. This new issuance is part of the company's strategic initiatives for capital funding aimed at supporting its ongoing research and development efforts. The offering will also include standard underwriter agreements to facilitate the sale and distribution of shares. The financial details surrounding the issuance, including price and expected proceeds, will be outlined further in the offering prospectus. This IPO marks a significant milestone for Enveric as it aims to enhance its market position and accelerate growth plans in the biotech sector.

Document Link: View Document

Form Type: CORRESP

Filing Date: 2025-01-30

Corporate Action: Ipo

Type: New

Accession Number: 000149315225004214

Filing Summary: Enveric Biosciences, Inc. submitted a request to the SEC for the acceleration of the effectiveness of its Registration Statement on Form S-1 (File No. 333-284277) on January 30, 2025. The request specifies an effective date of January 30, 2025, at 5:15 p.m. Eastern Time, or a later time as might be requested later by the company or its counsel. The company has designated Rasika A. Kulkarni from Dickinson Wright PLLC as the point of contact for confirmation of effectiveness or any inquiries.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-30

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225004213

Filing Summary: Enveric Biosciences, Inc. filed an amended S-1 registration statement with the SEC for its initial public offering (IPO). This amendment reflects updates to financial statements, revisions related to risk factors, and additional disclosures regarding the business model and market analysis. The offering will involve common stock and seeks to raise a specified amount to fund ongoing research and development activities in the biosciences sector. The document also outlines the potential use of proceeds, anticipated timelines for the offering, and the overall strategic vision of the company moving forward. Key amendments include detailed information on underwriters and the call for the application of funds raised.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-30

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225004292

Filing Summary: This document is Amendment No. 2 to the Form S-1 Registration Statement of Enveric Biosciences, Inc., filed on January 30, 2025. The amendment primarily serves the purpose of filing new exhibits without altering the preliminary prospectus or other sections of the registration statement. Key elements include updated exhibits related to the Wainwright Engagement Letter, and the inclusion of a consent from the independent registered public accountant. The document confirms that no new securities are being registered. Enveric Biosciences, Inc., which is classified as a smaller reporting company and an emerging growth company, plans to commence sales to the public as soon as practicable after the registration's effectiveness. The filing includes detailed descriptions and references to several multimedia exhibits and previous filings, highlighting ongoing financial collaborations and the company's adherence to the Securities Act of 1933 regulations.

Document Link: View Document

Form Type: S-1

Filing Date: 2025-01-14

Corporate Action: Ipo

Type: New

Accession Number: 000149315225002214

Filing Summary: Enveric Biosciences, Inc. filed an S-1 registration statement in connection with its initial public offering (IPO). The company aims to raise capital through the public sale of its stock, with details outlining the amount of shares to be sold, expected pricing, and potential use of proceeds from the offering. The document highlights the company’s business model, key financial metrics, competitive landscape, and future growth strategies, providing investors with essential insights into its operations and market positioning.

Document Link: View Document